Comparative Pharmacology
Head-to-head clinical analysis: ORTHO CYCLEN 21 versus ORTHO NOVUM 10 11 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO CYCLEN 21 versus ORTHO NOVUM 10 11 28.
ORTHO CYCLEN-21 vs ORTHO-NOVUM 10/11-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norgestimate. Suppresses gonadotropin (FSH, LH) release via negative feedback, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial structure to impair sperm penetration and implantation.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback inhibition of hypothalamic-pituitary axis, preventing ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg for days 1-7, norgestimate 0.215 mg/ethinyl estradiol 0.035 mg for days 8-14, norgestimate 0.250 mg/ethinyl estradiol 0.035 mg for days 15-21) orally once daily for 21 days, followed by 7 placebo tablets (if included) or 7 drug-free days, then repeat.
One tablet daily for 28 days, starting on day 1 of menstrual cycle. Each tablet contains 1 mg norethindrone and 10 mcg ethinyl estradiol for first 10 tablets, then 1 mg norethindrone and 35 mcg ethinyl estradiol for next 11 tablets, followed by 7 placebo tablets.
None Documented
None Documented
Terminal elimination half-life: Norgestimate metabolite (norelgestromin) ~28 hours; Ethinyl estradiol ~17 hours (range 13-27 hours). Clinical context: Steady-state achieved within 10-14 days.
Norethindrone: 5-14 hours; Ethinyl estradiol: 8-20 hours. Steady state reached within 5 days. Clinical significance: missed doses may increase pregnancy risk due to rapid decline.
Approximately 40% renal (as metabolites), 60% biliary/fecal (as metabolites). Norgestimate metabolites are excreted primarily in urine (40-50%) and feces (50-60%). Ethinyl estradiol metabolites are excreted in urine (40%) and feces (60%).
Renal (50-60% as metabolites, <10% unchanged); fecal (30-40%) with biliary elimination of conjugates.
Category C
Category C
Hormonal Contraceptive
Hormonal Contraceptive